Loading...
01/11 16:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary reflects a positive sentiment with strong financial performance, particularly a 32.3% revenue increase and improved gross margins. Product development is promising with new launches, and the strategic plan indicates market expansion. Despite increased operating expenses, the net loss is slightly improved. The Q&A section suggests confidence in future growth, although some responses were vague. Overall, the positive aspects outweigh the negatives, suggesting a likely positive stock price reaction.
Revenue for Q3 2025 $1.2 million, a 32.3% increase compared to $0.9 million in the same period last year. The increase was driven by a rise in the number of surgical procedures using the Catamaran system and the addition of sales from the newly acquired SImmetry SI Joint Fusion System.
Revenue for 9 months ended September 30, 2025 $2.5 million, in line with $2.5 million in the same period in 2024. No year-over-year change was noted.
Gross Profit for Q3 2025 $0.8 million or 66% of revenue, compared to $0.4 million or 47% in the prior year quarter. The improvement in gross margin was due to higher revenue absorbing fixed overhead costs in the cost of goods sold.
Gross Profit for 9 months ended September 30, 2025 $1.3 million or 54% of revenue, compared to $1.4 million or 54% of revenue in the previous year's period. No change in gross margin percentage was noted.
Operating Expenses for Q3 2025 $4.2 million, up from $3.6 million in the prior year period. The increase was primarily due to higher sales expenses driven by higher revenue, as well as higher marketing and G&A expenses related to the SiVantage acquisition integration.
Operating Expenses for 9 months ended September 30, 2025 $11.3 million, compared to $12 million in the prior year period. The decrease was driven by lower fixed expenses, including reduced stock-based compensation.
Net Loss for Q3 2025 $3.3 million or $0.40 per share, compared to a net loss of $3.2 million or $3.63 per share in Q3 2024. The slight increase in net loss was due to higher operating expenses.
Net Loss for 9 months ended September 30, 2025 $9.7 million, compared to $10.6 million in the same period in 2024. The improvement was largely driven by reduced operating expenses and lower fixed costs.
Cash Position as of September 30, 2025 $3.4 million, compared to $6.5 million as of December 31, 2024. The decrease was due to operational expenses and investments.
Catamaran SE SI joint fusion system: Full commercial launch of the Catamaran SE SI joint fusion system, featuring a reduced profile for greater flexibility in treating smaller SI joint anatomy or revision procedures. It supports a minimally invasive approach and includes a proprietary instrument set.
SImmetry+ SI joint fusion system: FDA 510(k) clearance for the SImmetry+ SI joint fusion system, which introduces advancements like 3D printed titanium implants and a simplified bone graft delivery system. Alpha launch planned with select physicians.
Portfolio expansion: Acquisition of SiVantage's SImmetry and SImmetry+ sacroiliac joint fusion technologies, transforming Tenon into a multiproduct company addressing a broader spectrum of sacropelvic fixation and fusion needs.
Physician education: Hosted 26 physicians in workshops to enhance peer-to-peer engagements and adoption of new technologies.
Revenue growth: Achieved record revenue of $1.2 million in Q3 2025, a 32% increase from the same period last year, driven by Catamaran procedure volumes and SiVantage portfolio integration.
Gross margin improvement: Gross profit increased to $0.8 million (66% of revenue) in Q3 2025, up from 47% in the prior year, due to higher revenue absorbing fixed overhead costs.
SiVantage acquisition: Acquisition of SiVantage's assets, including leadership team integration, enhancing commercial execution and innovation.
Regulatory milestone: FDA clearance of SImmetry+ SI joint fusion system, expanding minimally invasive surgical approaches and strengthening competitive position.
Regulatory and Clinical Milestones: While the company achieved FDA 510(k) clearance for the SImmetry+ system, regulatory hurdles and delays in broader market introduction could impact the timeline for revenue generation and adoption.
Integration of SiVantage Acquisition: The integration of SiVantage's assets and team, while progressing, involves higher marketing and G&A expenses, which could strain operational efficiency and financials if not managed effectively.
Operating Expenses: Operating expenses increased to $4.2 million in Q3 2025, driven by higher sales, marketing, and integration costs. This could pressure profitability if revenue growth does not keep pace.
Cash Position and Financing: The company ended Q3 2025 with $3.4 million in cash, down from $6.5 million at the end of 2024. While a $2.85 million PIPE financing was secured, reliance on external funding could pose risks if cash burn continues at a high rate.
Market Adoption and Competition: Despite strong demand for Catamaran and SImmetry systems, competitive pressures in the sacroiliac joint fusion market could challenge market share and pricing power.
Sales and Commercial Expansion: The company is actively onboarding sales professionals and expanding its commercial footprint. However, the effectiveness of this strategy in driving revenue growth remains to be seen.
Revenue Growth: The company expects continued revenue growth driven by increased demand for both Catamaran and SImmetry systems, supported by the recent SiVantage acquisition and expanded product portfolio.
Gross Margin Improvement: Gross margin is expected to improve as revenue increases and fixed overhead costs are further absorbed. Both SImmetry and Catamaran systems have a similar margin profile.
Product Launch and Market Expansion: The company plans an alpha launch of the SImmetry+ SI joint fusion system in the coming weeks, with broader market introduction guided by physician feedback. This is expected to strengthen the competitive position and expand market reach.
Sales Team Expansion: Tenon is actively onboarding sales professionals through a strategic hybrid structure to expand its commercial footprint and drive adoption of its product portfolio.
Regulatory and Clinical Milestones: The company aims to leverage recent FDA 510(k) clearance for SImmetry+ and ongoing clinical evidence to support broader adoption and payer coverage.
Financial Position: With $3.4 million in cash and an additional $2.85 million raised through PIPE financing, the company is positioned to execute its strategic growth initiatives.
The selected topic was not discussed during the call.
The earnings call summary reflects a positive sentiment with strong financial performance, particularly a 32.3% revenue increase and improved gross margins. Product development is promising with new launches, and the strategic plan indicates market expansion. Despite increased operating expenses, the net loss is slightly improved. The Q&A section suggests confidence in future growth, although some responses were vague. Overall, the positive aspects outweigh the negatives, suggesting a likely positive stock price reaction.
Despite some positive developments like the SiVantage acquisition and the upcoming Symmetry Plus launch, the company's financial performance shows significant declines in revenue, gross profit, and net loss compared to the previous year. Additionally, management's vague responses about the merger's financial impact and the uncertain timeline for Symmetry Plus launch contribute to negative sentiment. The economic uncertainty and market adoption risks further add to the concerns. The lack of strong guidance or shareholder return plans also supports a negative outlook for the stock price in the short term.
Despite some positive developments like the SE platform launch and patent expansions, the earnings call reveals significant challenges. Minimal revenue growth, continued net losses, and reimbursement issues are concerning. The Q&A shows some optimism about future growth, but vague responses and expected increases in operating expenses suggest uncertainty. Equity financing and lack of debt are positives, but the overall sentiment leans negative due to weak financial performance and ongoing risks.
The earnings call presents a mixed outlook. While there is revenue growth and cash position improvement, gross margin has declined, and the company faces reimbursement and competitive pressures. The upcoming SE platform launch and market expansion are positive, but uncertainties in revenue trajectory and market adoption persist. The Q&A reveals positive physician interest but lacks clarity on growth timelines. Given these factors, the stock price reaction is likely to be neutral.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
